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Purdue University, West Lafayette, Indiana, USA,
(Resuscitation, 57, 245-255, 2003)

Abstract
Objective: To present and demonstrate a new simplified method for synthesizing results
of multiple clinical trials in resuscitation research. Methods: The mean difference across
studies in the proportion of favorable outcomes between experimental and control groups
is calculated. This difference is shown to have a t-distribution. Its significance can be
ascertained with a simple t-test. The analysis can be implemented in a one-page
computer spreadsheet. Results: Simplified meta-analysis provides high sensitivity and
can be extended to include weighting of studies according to size or quality, comparison
of subgroups of studies, tests for outliers, and calculation of the power of the meta analysis. Sample analyses are presented for two experimental forms of cardiopulmonary
resuscitation: interposed abdominal compression CPR and active compressiondecompression CPR. Conclusions: Traditional narrative reviews, taking note of the
proportion of individual studies with statistically significant results, can lead to erroneous
conclusions and unnecessary delays in the clinical use of research findings. Simplified
meta-analysis can provide rapid, quantitative, and accurate estimates of the amount of
benefit or harm from an experimental intervention and can further empower physicians to
practice evidence-based medicine.
Keywords: Abdomen, Active compression-decompression CPR, Clinical trials,
Guidelines, Interposed abdominal compression-CPR, Methodology, Statistical analysis
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1. Introduction

A key aspect of evidence-based medicine is the careful analysis of research literature
concerning the effectiveness of a proposed novel treatment or procedure. Traditional
methods of research synthesis involve tabulating the available studies that are related to a
particular treatment or innovation and noting the number of significant positive stu dies
versus the number of non-significant ones. This procedure has been termed “vote
counting”, in which each study casts a vote for or against the innovation under
consideration 1-3 . The proportion of positive studies required to justify a change in
clinical practice may vary among reviewers and regulatory bodies. In the usual collective
review a positive recommendation is made when a majority, or more, of trials are
statistically significant. If there are equal numbers of statistically significant and nonsignificant clinical studies, many reviewers will conclude the vote to be a draw and
recommend that more research is needed3.
The vote counting approach to research review is now known to lead systematically to
high percentages of erroneous conclusions 1-3. In particular, vote counting produces Type
II statistical errors or false negative evaluations—that is, erroneously accepting the null
hypothesis when the results of treatment are quite genuine2, 4. Conventional testing for
statistical significance minimizes the probability of Type I errors or false positive
evaluations—that is, erroneously concluding there is a real treatment effect when the
results are due to sampling variability. However, consideration of conventional statistical
significance does not protect against Type II errors.
Meta-analysis, defined as the quantitative synthesis of data from multiple clinical studies,
minimizes both Type I and Type II errors. This approach is gaining popularity as an
alternative to vote counting5-11 . The present paper introduces a simple and user-friendly
form of meta-analysis for use by groups of physicians and others seeking to set evidencebased practice guidelines. It is an extension and simplification of the “observed minus
expected” (O-E) approach of Yusuf and Peto5, 12, combined with the concept of
cumulative meta-analysis introduced by Lau 6. This simplified approach to meta-analysis
has a number of advantages for systematic overviews of clinical trials.
1. The method is derived easily from fundamental principles and can be understood,
verified, and trusted by physicians with knowledge of elementary statistics as taught
in universities and medical schools. It is designed to demystify meta-analysis and to
place control of the technical aspects of the process directly in the hands of clinical
decision-makers. These decision makers can then combine clinical judgment with
statistical inference to arrive at the best possible decisions about the timely adoption
of new methods reported in the research literature.
2. It is easily performed. All that is needed is a basic spreadsheet program such as
Microsoft Excel. Given a spreadsheet template, one can perform the technical
computations for a meta-analysis about as easily as making a table of results from a
literature survey. Special purpose software is not required.
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3. It allows for a variety of optional calculations. These include the number needed to
treat (or harm), the weighting of studies according to their size, quality, or category, a
procedure for detecting outliers, calculation of the power of the meta-analysis, and
easy comparison of subgroups of studies.
Here the method is described and illustrated with reviews of two newer techniques in
cardiopulmonary resuscitation.
2. Methods
Suppose that one reviews a series of m randomized clinical trials and that in each trial
an experimental group is compared with a control group and survival is the principle
outcome measure. The proposed method focuses upon the differences in the proportions
of survivors (or other favorable outcomes) in each study, which is denoted p. To say
“the experimental treatment increased survival by 15 percent,” is to say p = 0.15. Any
dichotomous outcome measure, indicating either benefit or harm, may be used in the
place of survival. These might include the occurrence of tumor response, death, stroke, a
significant cardiac event, the development of lung cancer, graft patency after one year,
etc. If some studies measure harm (e.g. mortality) rather than benefit (e.g. survival), it is
a simple matter to recast results in terms of the proportions of patients with favorable
outcomes, so that the direction of the results is consistent for all studies.
2.1 Testing the mean difference in outcome
Let p1 be the proportion of favorable outcomes in a control group of n 1 patients. Let p 2
be the proportion of favorable outcomes in an experimental group of n 2 patients. Let the
corresponding values p1i , p 2i , n1i , n 2i represent results of the i-th study in a series of m
studies to be synthesized, and let p i  p 2 i  p1 i be the difference in the proportions of
favorable outcomes observed in the i-th study. Definitions of these and related variables
used in the analysis are summarized in Table 1.
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Table 1. Notation
Variables

Definitions

m

Number of studies in a series of studies to be
analyzed
Number of patients in a study group
Measured proportion of survivors in a control
group or an experimental group
Difference in proportions of survivors
(experimental – control)
Standard deviation of random variable, X
Variance of random variable, X
Optional weighting factor for a particular study
Sum of weighting factors for all studies in a
series to be analyzed

n
p
p
s(X)
s2(X)
w
W
Subscripts
1
2
i, j

Control group
Experimental group
Any single study in series of studies

The p1 i ' s , p 2 i ' s , and p i ' s are random variables that depend upon the true probabilities
of favorable outcome in the various experimental and control groups and also upon
sampling variability. Suppose that each trial were repeated a large number of times and
the null hypothesis were true. That is, there is no real treatment effect. Then for each
study, i, the difference in the proportions of favorable outcomes, p i  p1 i  p 2 i ,
between experimental and control groups would have zero mean and variance best
estimated as

s 2 (p i ) 

p1i (1  p1i ) p 2i (1  p 2i )

.
n 1i  1
n 2i  1

(1)

Expression (1) is based upon the principle that the variance of a sum or difference of
independent random variables equals the sum of the variances13. The control and
experimental results are independent, because they come from different patients. The
p (1  p)
variance estimates of the form
for the measured proportions of survivors in the
n 1
control and experimental groups are unbiased, as shown in Appendix 1. All data needed
to evaluate expression (1) are readily obtained from published results.
Assume initially that the studies to be synthesized are given equal weights. (Use of
unequal weights, based for example upon study quality or size, is discussed in the next
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section, 2.2.) The test statistic to be used in meta-analysis is the mean difference in
proportions for the m studies, namely

p 

p1  p 2    p m
.
m

(2)

Under the null hypothesis the expected value of p is zero. Again, since the variance of
a sum or difference of such independent random variables is the sum of the variances 13,
the estimated variance of p is

 

s 2 p 

s 2 (p1 )  s 2 (p 2 )    s 2 (p m )
.
m2

 

(3)

Thus s 2 p is easily calculated from the p1 , p 2 , n1 , n 2 data for the various studies.

 

Taking the square root to obtain s p , we can compute the test statistic,

t

p

 

s p

.

(4)

One can show, along the lines of Welch14 , that this test statistic is distributed very much
like a “Student” t-distribution with a number of degrees of freedom roughly equal to
twice the total number of survivors in all of the studies to be synthesized *, that is, a tm

distribution with df  2 p1i n 1i  p 2i n 2i . Note that a t-distribution with more than about
i 1

50 degrees of freedom is equivalent to the normal distribution. Thus for all most metaanalyses one can simply use the normal distribution.
To construct 95% confidence intervals for p , let t97.5 be the 97.5th percentile of the tdistribution with df degrees of freedom, as found in standard tables or functions.
Typically this value is close to 2.0. For the normal distribution t 97.5 = 1.96. The 95
percent confidence interval for p is p  s p  t 97.5 . If this confidence interval

 

includes zero, one cannot reject the null hypothesis that p = 0 at the P = 0.05 level. If
the confidence interval does not include zero, there is a significant positive or negative
effect of treatment across studies.

*

A slightly better approximation can be obtained using the formula df = 2S(1+3(S/N)), where S is the total
number of survivors in all studies and N is the total number of patients in all studies. If a majority of
patients in all studies survive, then one should replace the number of survivors with the number of
non-survivors.
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2.2 Optional features of the analysis
Weighting of studies. In expression (2) p is an un-weighted average, to which all
studies contribute equally, in keeping with the recommendation of Peto, Collins and
coworkers.12, 15. If one wishes to deal with varying size or quality of the studies by
introducing weights so that some studies contribute more to p than others, then for a
weighted average with individual study weights w i and sum of study weights W,

p 

w 1 p1  w 2 p 2    w m p m
,
W

(5)

 

w 12 s 2 (p1 )  w 22 s 2 (p 2 )    w 2m s 2 (p m )
,
s p 
W2
2

(6)

 

and the 95% confidence interval for p is  s p  t 97.5 , as before.
Weights may be assigned to reflect the sizes (n’s) of various studies, such that a large
study counts for more than a smaller one. One such approach1, 16-18 uses inverse variance
estimates as a weighting factors. In this case weights are calculated as w i  1 s 2 (p i ) .
The inverse variance values are larger for larger and better-controlled studies. This type
of weighting is especially recommended when combining several initial small trials with
subsequent larger trials. Inverse variance weights produce minimum variance of the
overall weighted average19, 20. Subjective ratings of study quality can also be used as
weights. However, the value of reviewers’ impressionistic ratings of the quality or
worthiness of studies is controversial21, 22.
The mathematics of the present method accommodates both users who argue that unequal
weighting of studies is arbitrary and capricious and also those who argue that equal
weighting ignores obvious differences in study quality and size. For reviewers of the first
persuasion all weights are simply set to 1.0. For reviewers of the second persuasion each
individual study is weighted according to predetermined criteria. The use of inverse
variance weighting is a popular compromise strategy and is rapidly becoming standard
practice in medical meta-analyses. Typically, the main results of the meta-analysis will
be insensitive to easily tested changes in the weighting method, providing evidence that
the weights were not chosen to produce a particular result.
The inclusion of weighting factors in the mathematics and in spreadsheets for performing
the analysis also has practical advantages. An examination of the influence of various
individual studies upon the outcome of the meta-analysis can be done by the simple
expedient of setting the weight of a particular study to zero. If the significance of the
overall analysis changes greatly, then a single study is driving the results. By extension,
analysis of sub-groups of studies can be performed by using non-zero weights for
particular studies of interest and zero weights for all other studies.
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Subgroup comparison. Suppose one finds among the studies in a meta-analysis two
apparent subgroups of studies that differ in treatment effect, possibly on the basis
differences in patient populations, treatment implementation, or clinical setting. To test
whether there is there a significant difference in the treatment effect between the
subgroups one can re-do the meta-analysis twice—first setting the weights for subgroup 2
to zero, leaving subgroup 1, and then setting the weights of subgroup 1 to zero, leaving
subgroup 2. If the 95% confidence intervals do not overlap and just touch at one
common point, then the results for one subgroup will be greater than the results for the
other subgroup at least (0.975)2 = 95.0625 percent of the time. In this sense one can say
that if the 95 percent confidence intervals of p for mutually exclusive subgroups of
studies do not overlap, then the subgroups are significantly different from each other. In
many cases of apparent differences among studies, the 95 percent confidence intervals
will overlap1, 3. Then one can avoid needless speculation over differences consistent with
sampling variation alone. If the 95 percent confidence interval for a subgroup of m=1
study is clearly separated from that for the remaining m-1 studies, then the study may be
unidentified as an outlier.
Number needed to treat (or harm). An omnibus number needed to treat can be calculated
1
as
. This statistic, advocated by McQuay and Moore 23, represents the average
p
number of patients that must be given an experimental treatment to obtain one additional
survivor (or other good outcome). It is useful in evaluating the cost effectiveness of
proposed innovations.
Power of the meta-analysis. Under the null hypothesis the mean value of the distribution
p
of t 
is zero, and the standard deviation of t is very close to 1.00, unless the
s p
aggregate number of survivors is very small. In this case one can also calculate the
power of the meta-analysis for the alternative hypothesis that the true effect is at least,
say, a 10 percent difference in the proportion of survivors. Then, for the alternative
0.10
hypothesis p1 = 0.10 , we have t 1 
. The statistical power of the meta-analysis is
s p
the probability of making a correct positive evaluation of the experimental treatment,
assuming the alternative hypothesis is true. Using P = 0.05 for significance testing, the
power is

 

 

F(t 1  1.96) ,

(7)

where F is the cumulative probability density function for the standard normal
distribution.* The usefulness of computing the statistical power of a meta-analysis has
been emphasized recently by Hedges and Pigott24.
*

In Microsoft Excel this function is named NORMSDIST().
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2.3 Spreadsheets for performing meta-analysis
A standard spreadsheet program such as Microsoft Excel is sufficient to perform a
simplified meta-analysis. In one compact format, each study is represented in a column
of the spreadsheet. Successive steps in the calculations are performed in successive rows
of the spreadsheet. Top rows include the study author, the study weight, the number of
favorable outcomes and total number of patients in control and experimental groups.
Subsequent rows include control and experimental group proportions, the p i for each
study, and its variance estimate (1). The next rows include the intermediate variables
w i p i , w i2 p i and w i2 s 2 (p i ) for weighted study calculations. Then p and its 95%
confidence limits are calculated using expressions (4), (5) and (6) together with the tdistribution and inverse t-distribution functions. Finally the number needed to treat and
power of the meta-analysis are calculated. Excel’s SUMIF(weight > 0) and
COUNTIF(weight > 0) functions can be utilized across columns to implement a new
cumulative meta-analyses after the appearance of each successive study. Then each
successive column represents a cumulative meta-analysis at one point in time. For
inverse variance weighting of the studies, the weights are assigned values equal to
1 s 2 ( p i ) .
3. Results—sample analyses
Sample meta-analyses were performed on studies relating to two experimental techniques
of cardiopulmonary resuscitation (CPR). The first is the addition of interposed
abdominal compression (IAC) to otherwise standard CPR 25-27. The second is CPR with
active compression and decompression (ACD) of the chest 28-30. Reviews of these
techniques are found in references 27, 31 and 32. During IAC-CPR positive pressure is
applied to the abdomen in counterpoint to the rhythm of chest compression, so that the
abdomen is being compressed when chest pressure is relaxed. During ACD-CPR
positive and negative pressures are applied alternately to the chest by means of a
“plunger” that forms a seal with the anterior chest wall. Both methods improve
hemodynamics in animal studies of electrically induced ventricular fibrillation 33, 34. Both
improve CO2 excretion as a measure of effective systemic perfusion in human
resuscitations35, 28, 36.
Relevant full length, peer reviewed publications were identified using evidence
evaluation worksheets created by the research working group of the American Heart
Association37, 38. Individual trials were obtained from MEDLINE searches, the author’s
files, and reference lists of review articles on newer techniques in resuscitation as
referenced in39. The end points analyzed include short-term survival and long-term
survival. Short-term survival is defined as return of spontaneous circulation (ROSC).
Long-term survival is defined as hospital discharge with intact neurological function.
Results of simplified cumulative meta-analysis for IAC-CPR are shown in Table 2 and
Figure 1. Results of simplified cumulative meta-analysis for ACD-CPR are shown in
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Table 3 and Figure 2. Tables 2 and 3 were copied from a working spreadsheet, a
template for which can be obtained from the author at no cost and modified by the user
for similar meta-analyses. The top rows in Tables 2 and 3 show raw data abstracted from
individual studies. The last five rows of Tables 2 and 3 show data for a cumulative metaanalysis. In these bottom rows successive columns from left to right represent successive
stages of the cumulative meta-analysis. The mean p -value under Study 1 describes the
first study only. The mean p -value under Study 2 describes the combined results of the
first two studies. The mean p -value under Study 3 describes the combined results of
the first three studies, etc. The cumulative nature of the data in the next four rows is
similar.
Table 2. Cumulative meta-analysis for ROSC and discharge survival data in studies
of IAC-CPR. Here studies are given inverse variance weights, 1/s2(p)
ROSC

Discharge

Raw data

Last Study ID
Study Weight
Study #
# Cont Alive
n1
# Exp Alive
n2

Mateer
349.93
1
45
146
40
145

Ward Sack 1 Sack 2
40.47 116.25 154.96
2
3
4
3
14
21
17
55
76
6
29
33
16
48
67

Ward
256.00
2.1
0
17
1
16

Sack 1
255.75
3.1
3
55
8
48

Proportions

p1
p2
p
2
s (p)

0.3082
0.2759
-0.0324
0.0029

0.1765
0.3750
0.1985
0.0247

0.2545
0.6042
0.3496
0.0086

0.2763
0.4925
0.2162
0.0065

0.0000
0.0625
0.0625
0.0039

0.0545
0.1667
0.1121
0.0039

p

-0.0324

0.0831 0.1719 0.1830

0.0625

0.0873

SE p
2-tail P(t)
NNT
Power

0.0535
0.5458
-30.9
0.46

0.0506 0.0444 0.0389
0.8680 0.0983 0.0062
12.0
5.8
5.5
0.51
0.61
0.73

0.0625
0.4226
16.0
---

0.0442
0.0599
11.5
0.62

Cumulative data
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Table 3. Cumulative meta-analysis for ROSC data in studies of ACD-CPR
using inverse variance weights, 1/s2(p)
Last Study ID

C93N

T94J

L94J

S95J1

S95J2

67.56
1
9
30
20
32

55.32 131.79 416.61 949.51
2
3
4
5
9
24
27
65
28
77
136
310
15
24
20
56
25
53
117
297

L96J

S96J1

S96J2

S96R

P97C

Raw Data

Study Weight
Study #
Cont Alive
n1
Exp Alive
n2

56.36 878.88 1761.87 221.72 557.88
6
7
8
9
10
12
129
84
68
77
30
386
510
114
258
10
140
91
54
114
26
405
501
106
254

Proportions

p1
p2
p
2
s (p)

0.3000
0.6250
0.3250
0.01480

0.3214
0.6000
0.2786
0.01808

0.3117
0.4528
0.1411
0.00759

0.1985
0.1709
-0.0276
0.00240

0.2097
0.1886
-0.0211
0.00105

0.4000
0.3846
-0.0154
0.01774

0.3342
0.3457
0.0115
0.00114

0.1647
0.1816
0.0169
0.00057

0.5965
0.5094
-0.0871
0.00451

0.2984
0.4488
0.1504
0.00179

Cumulative
Data

p

0.3250 0.3041 0.2198 0.0663 0.0151 0.0140 0.0132 0.0147 0.0097 0.0251

SE p 0.1217 0.0902 0.0627 0.0386 0.0248 0.0244 0.0198 0.0152 0.0148 0.0140
2-tail P(t) 0.0098 0.0011 0.0006 0.0878 0.5447 0.5657 0.5061 0.3344 0.5123 0.0732
NNT
3.1
3.3
4.6
15.1
66.4
71.2
76.0
68.0
102.8
39.8
Power
0.13
0.20
0.36
0.74
0.98
0.98
1.00
1.00
1.00
1.00

In Table 2 the four data columns to the left represent a meta-analysis of short-term
survival. The two columns to the right represent a separate meta-analysis of long-term,
discharge survival. Studies of IAC-CPR showed a significant treatment effect for both
short-term and long-term survival. p is 10.7 percent for ROSC, 8.7 percent for hospital
discharge. The effect of IAC is highly significant for ROSC data
(P = 0.006) and of borderline statistical significance (P = 0.06) for discharge survival
data. These summary values can be immediately converted into the number-needed-totreat, NNT  1/ p , the number of patients that must be treated to obtain one additional
survivor23 . For return of spontaneous circulation the NNT is 9. For discharge survival,
the corresponding NNT is 12. The last row in Table 2 demonstrates that the process of
cumulative meta-analysis gradually increases the statistical power for detecting a true
positive treatment effect. Here power was calculated using expression (7) and assuming
a true positive treatment effect of p = 10%. Increasing statistical power reduces the
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probability of a false negative evaluation or Type II error, which is equal to one minus
the power.
Figure 1(A) shows a cumulative meta-analysis plot for IAC-CPR to demonstrate
historical trends with the publication of each successive study. The top data point and its
95 percent confidence interval represent the historically first trial, the next a combination
of the first two trials, the third a combination of the first three, etc. These data points
correspond to the successive meta-analyses of ROSC data in the columns of Table 2 from
left to right. Statistical significance typically emerges after publication of just a few
studies to reach a stable value. Thereafter, the addition of further studies merely narrows
the 95 percent confidence interval.

Mean Difference in Proportion of Survivors
-0.2

-0.1

0.0

0.1

0.2

0.3

0.4

0
ROSC
Discharge
Zero line

Cumulative Studies

1

IAC-CPR
(A)
2

3

4

5

Figure 1(A)
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Mean Difference in Proportion of Survivors
-0.2

-0.1

0.0

0.1

0.2

0.3

0.4

0
ROSC
Discharge
Zero line

1

Cumulative Studies

IAC-CPR
(B)
2

3

4

5

Figure 1(B)
FIGURE 1 . Simplified cumulative meta-analysis for IAC-CPR. Successive
points from top to bottom represent a separate meta-analysis after the
appearance of each study in the series. (A) Equal weighting: each study is
assigned weight 1.0. (B) Inverse variance weighting: each study is assigned
weight , 1/s2(p). The major conclusions of the meta-analysis are independent
of the weighting method.
The cumulative meta-analysis shown in Figure 1(A) was conducted with equal study
weights in keeping with the recommendation of Peto12. The corresponding cumulative
meta-analysis in Figure 1(B) was conducted with inverse variance weights in keeping
with the recommendation of Hedges1, 17. The raw data for Figures 1(A) and 1(B) were
identical. For dichotomous variables such as survival, individual study variances are
highly dependent upon group size, as indicated in Equation (1). As expected, inverse
variance weights diminish the impact upon the overall results of
Study 2, which had small patient numbers. However, the major conclusions of the meta analysis of IAC-CPR are insensitive to the particular weighting method used.
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Critics often object to one study or another on technical grounds. Because the number of
studies in the IAC series is small, the question arises "would the analysis be significant if
the offending study were left out?" Table 4 shows results of meta-analysis of ROSC data
for IAC-CPR, in terms of 95 percent the confidence limits for p when each of the 4
studies in turn is given zero weight in the analysis. A zero weight has the effect of
excluding one particular study and can be assigned very easily in a spreadsheet format by
changing the weight value to zero. Here the results, for inverse variance weighting, show
that at least one of the studies by Sack, each of which included different patients, is
needed to conclude that IAC-CPR produces more frequent ROSC than standard CPR.
Table 4. Sensitivity testing: effects of omitting single studies upon 95% confidence
intervals for p ; ROSC data for IAC-CPR versus standard CPR
Study omitted
None
Mateer
Ward
Sack 1
Sack 2

Lower 95% limit

Upper 95% limit

0.031
0.152
0.022
-0.029
-0.014

0.184
0.375
0.180
0.140
0.162

At least one of the studies by Sack, which included different patients at different
institutions, is needed to conclude that IAC-CPR produces more frequent ROSC than
standard CPR.
Retrospectively, there does appear to be a difference in the benefit of IAC-CPR between
the three in-hospital studies and the one pre-hospital study. A separate meta-analysis of
the three inverse variance weighted in-hospital studies (numbers 2, 3, and 4) for ROSC
data gives p = 26 percent with a 95% confidence interval from 15 to 38 percent. This
range does not overlap the 95% confidence interval of the one pre-hospital study, which
ranged from -14 to +7 percent. (In the pre-hospital study patients assigned to IAC-CPR
necessarily received some standard CPR from bystanders and also during transport to the
hospital, perhaps diluting the effect of IAC.) Thus for in-hospital resuscitations, one can
conclude from the three studies that IAC-CPR roughly doubles rates of initial
resuscitation from about 25 to about 50 percent. For the two in-hospital studies of longterm survival with IAC-CPR also appeared to double from about 8 to 16 percent.
However, the total number of patients studied for long-term survival is small and the
result is of borderline statistical significance (P = 0.06).
A simplified meta-analysis of studies of ACD-CPR using equal weights for each study
showed a statistically significant treatment effect for ROSC, with p equal to 7.7 percent
(data not shown). However, when inverse variance weighting was used to emphasize the
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relative importance of larger, better-controlled studies, p for ROSC was reduced to 2.5
percent. The 95% confidence interval for p was –0.002 to 0.053, just including zero.
For hospital discharge p was less than 0.01 and clearly not significant. Figure 2 shows
a cumulative meta-analysis plot for ACD-CPR with inverse variance weights. Here the
pattern is unusual in that early studies show a much greater effect than do later ones, with
a trend toward zero until publication of the very last study, which was significantly
positive individually.

Mean Difference in Proportion of Survivors
-0.2

-0.1

0.0

0.1

0.2

0.3

0.4

0
1
2

Cumulative Studies

3
4
5
6

ROSC
Discharge

7
8

Zero line
ACD-CPR

9
10
11

FIGURE 2. Simplified cumulative meta-analysis for ACD-CPR using inverse
variance weighting.

14

Evidently, the studies of ACD-CPR were not all cast from the same mold. Inspection of
the p values reveals one group of studies indicating a significant positive benefit
(studies 1, 2, 3, and 10) and a second group having zero benefit upon survival (studies 4 9). The 95 percent confidence interval for p in the first group of studies is 0.10 to 0.24.
The 95 percent confidence interval for p in the second group of studies is -0.03 to
+0.03. Although this subgroup analysis was performed retrospectively with knowledge
of the results, the impression for the ROSC data is unmistakably bimodal and not that
expected for a homogeneous population. Those close to the research suggest rigorous
training in the technique, which is physically more difficult to perform than standard
CPR40 , is required for good results. Such training was clearly described in the last
positive trial, and was probably done in the first few positive trials. This effect cannot be
demonstrated for long-term survival following ACD-CPR, however, which is uniformly
similar to that for standard CPR.
4. Discussion
Research is producing growing numbers of important innovations in healthcare generally,
and in the field of resuscitation in particular. However, there are often years of delay
between achievement of positive results in valid research studies and their subsequent
implementation in routine clinical practice6, 41, 42. One reason for delayed implementation
of research findings is the excessive processing and analysis that evidence requires before
application41 . Busy individual clinicians have limited time to pour over seemingly
conflicting data. Panels of experts meet for at most a few days to consider multiple
practice guidelines in rapid succession with no time scheduled for seeking answers to
questions that arise. Overly complex statistical analysis is simply avoided by such
panels, and conservative conclusions are drawn, often using an explicit or implicit votecounting approach that is biased toward Type II errors10.
Simpler, user-friendly techniques of research synthesis are needed to bridge the gap
between research and practice. Simpler techniques of meta-analysis would empower
more physicians to practice evidence-based medicine, especially in conjunction with the
increased availability of the necessary raw data on the Internet. Such techniques
implemented on laptop computers with standard software would allow guideline-writing
groups to address a variety of "what if" questions in the process of deliberation, such as
"what if this particular study were left out" or "what if certain high quality studies
counted more".
This paper presents an approach to meta-analysis of a series of two-group clinical trials
that is straightforward both in theory and in execution. The simplification of technical
mathematics, which leads to a t-test of the overall significance of included studies, makes
the approach personally verifiable by physician analysts. The actual calculations require
no more than a one-page spreadsheet. One can create or borrow, and validate, a sample
spreadsheet quickly. Subsequent meta-analyses can be done easily by replacing the raw
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data in the sample spreadsheet with raw data from other studies and expanding or
contracting the table appropriately. Special purpose software is not needed.
Assumptions of the method are few. One is that the variance of a sum of independent or
uncorrelated random variables equals the sum of the variances13 . This assumption is
reasonable since the component p values are derived from independent studies. (It is
important to confirm that the same patients do not reappear in more than one study, as
can happen with a preliminary report and a final report of an ongoing trial.) The use of a
t-distribution for expression (4) requires the further assumption that the average
difference in proportions will be normally distributed. This assumption is reasonable,
since the component binomial distributions approach the normal distribution in shape for
group n’s > 20 (true for all but the very smallest clinical trials) 13 . As the number m of
studies that are combined increases, the central limit theorem13 further strengthens this
assumption. Finally, the assumption that a normally distributed random variable, divided
by its estimated standard deviation has a Student’s t distribution, as originally described
by Welch14, is well precedented in statistics and can be confirmed for proportional data
by numerical examples.
Meta-analysis in terms of the proportional differences, pi , is especially significant for
those assumptions that are not present. Just as in the summed observed minus expected
method of Yusuf, Peto, and coworkers5, there is no assumption of homogeneity. The test
statistic p is treated simply a weighted sum of random variables. Hence expressions (2)
through (6) do not require that the p i ' s be similar in magnitude.
The studies may vary in terms of patient populations, drug doses, procedural skills,
hospital settings, exclusion criteria, etc. It is not necessary to assume that the trials
synthesized are exactly comparable—only that they test the same basic intervention as it
might be implemented in various settings in the real world. The p i ' s need not even
measure proportions of exactly the same things. One study could measure proportion of
24-hour survivors and another study could measure the proportion of 48-hour survivors
after the same treatment. A reviewer might ask the question: “is there evidence of
treatment effect upon long term survival?” The meta-analysis combining these studies is
perfectly valid as long as “long term” is clearly defined as 24 hours or greater. Similarly,
if some studies measured mortality and others measured the occurrence of stroke or
myocardial infarction, they could be combined, as above, in a meta-analysis of clearly
defined “major adverse outcomes” following standard vs. experimental therapy.
For those accustomed to the high false negative results of traditional literature reviews
and research synthesis1, 3, meta-analysis may seem to be a rush to judgment, provoking
one or more now classical objections3, 21. Each objection is a variation on the common
theme that “you shouldn’t combine apples and oranges”. One such concern is the
challenge of dealing with multiple end points recorded in individual studies, such as longterm survival (apples) and short-term survival (oranges). Strictly speaking, ROSC and
discharge survival data from the same studies of experimental CPR cannot be combined
in the same simplified meta-analysis because they are not independent. A conservative
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and now technically easy remedy, as shown in Figures 1 and 2, is to perform a separate
analysis for each type of end-point, even though the number of studies measuring a less
popular or hard to obtain end point, like discharge survival, may be smaller.
A second objection relates to variable methodological quality of included studies,
although subjective quality ratings do not necessarily correlate with the size of treatment
effects3, 21, 22. Critics argue that less worthy studies (apples) should not be compared with
more worthy studies (oranges). This issue can also be dealt with empirically. Should
subjective quality ratings be available and agreed to, one can perform a separate metaanalysis (subgroup comparison) for studies of high and low quality by alternately setting
the weights of low and high quality studies to zero. If the results differ, one can rely on
the “strong” studies; if they do not, then all studies should be included3.
A third objection to meta-analysis relates to variable research methods among studies
with different patient populations, exclusion criteria, data recording methods, hospital
settings, or other kinds of “apples and oranges”. Again this objection can be answered
empirically. One may simply perform a separate meta-analysis for each class of
studies—that is, perform a subgroup comparison. If the 95% confidence intervals for the
p values for two subgroups do not overlap, then one has statistical evidence for a case of
apples and oranges. Otherwise one only has evidence for normal sampling variation.
Thus, all three classical objections to meta-analysis can be dealt with by doing a separate
meta-analysis of the apples versus the oranges. Heated philosophical debates can be
attenuated by taking a closer look at the data.
Earlier workers in the field of meta-analysis anticipated several aspects of the approach
presented in this paper. The method of Rosenthal and Rubin43 began with reported pvalues as inputs and later16 included differences in proportions. The present approach
represents a fresh look at the problem from the standpoint of the physician. In this
context meta-analysis is a tool that must be used in conjunction with clinical judgment.
In the first phase of evaluation of a new intervention one is simply trying to determine if
a proposed treatment, in general, produces an effect on survival or some other favorable
outcome12. If it does, then the effect seen in the selected trials is likely to generalize to
the even broader range of circumstances found in widespread practice. As more data
become available a second phase of meta-analysis may be done to determine if a
particular intervention produces different outcomes in particular patient groups. The
present method can be used to help answer both of these questions. Simplified meta analysis provides a tool to distill relevant data, but, of course, it cannot substitute for
sound clinical judgment in dealing with the sensitive issues of life and death and quality
of life.

17

Conclusion
Meta-analysis allows the reviewer to deal with the situation of multiple small studies
having promising effects but small n’s and somewhat varying methodology, owing to
limitations of cost, time, patient recruitment, or the inherent difficulty of resuscitation
research. Formal meta-analysis is immune from the systematic and excessive Type II
errors associated with the traditional "vote-counting" methods of research synthesis2, 4.
Such analysis can guide individual and institutional practice and shorten the time between
medical research discoveries and their clinical implementation. The method presented
here makes meta-analysis accessible to any physician.
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Appendix 1: Estimating the variance of a binomial distribution from measured
proportions.
Let p be the measured proportion of survivors among n treated patients, for whom the
true probability of survival is . The mean (expected value) of the binomial distribution
of p-values is E(p) =  and the variance, V(p), of the binomial distribution is
V(p) = (1- )/n . It is well known that the maximum likelihood estimate of  is p 13 .
In turn, the maximum likelihood estimate of V is V̂(p)  p (1  p) / n . This expression
provides an initial estimate of the binomial distribution variance.
Let us check the expected value of V̂(p)  p (1  p) / n to see if it is biased compared to
the true variance V(p).

E(V̂) 

E(p) E(p2 )

n
n

A1.1

By definition,
V( p)  E ( p  ) 2   Ep2  2p  2   Ep2   2Ep   2  Ep2   2

A1.2

Combining the above,

E(V̂(p)) 

 V(p)   2  (1  ) V(p)



n
n
n
n

A1.3

But  (1- )/n = V(p), so

 1
 n 1
E(V̂(p))  V(p) 1    V(p) 

 n
 n 

A1.4

The initial estimate is biased by a factor of (n-1)/n. However, if we multiply this estimate
by a factor of n/(n-1) the bias is removed. Hence,

V̂(p) 

p (1  p) n
p (1  p)


n
n 1
n 1

is unbiased, as can be confirmed by repeating steps A1.1 through A1.4 for the new
estimate.

